Trastuzumab, the humanized monoclonal antibody targeting the extracellular domain 4 (ECD4) of the HER2 receptor [52], was first approved as a therapeutic antibody in 1998 for HER2-positive breast cancer as a single agent or in combination with paclitaxel [65,66]. The gene discussed is ERBB2; the disease is breast carcinoma.